Survey responses from patients with advanced cancer revealed that there were gaps in knowledge across various aspects of immunotherapy treatment, including about side effects and curative potential.
Surveying a group of patients with advanced cancer, a group of researchers has identified room for improvement in educating patients on the risks, benefits, and curative potential of immunotherapy.
The findings highlight the benefit of providing patients with educational tools so they can better understand what to expect with immunotherapy treatment.
All 105 patients who responded to the 9-question survey had received immunotherapy for either stage IV or unresectable stage III melanoma or non-small cell lung cancer (57 had melanoma and 48 had ung cancer). Immunotherapy treatments included pembrolizumab, ipilimumab and nivolumab, and atezolizumab.
Participants had a median age of 69 years and 33% were female. Most had completed at least a year of college (76.7%) and 73.3% felt “very” or “extremely” confident filling out medical forms.
Survey responses revealed that there were gaps in knowledge across various aspects of immunotherapy treatment, including how immunotherapy works. For example, when asked if immunotherapy and chemotherapy both work by killing all rapidly dividing cells in the body, approximately 25% of patients answered “true.”
Some patients also showed misconceptions in the side effects associated with immunotherapy, including if side effects are always mild and reversible, if treatment can affect any organ, if medications like steroids are sometime needed to control side effects, and when the side effects can occur.
“Participants in this study lacked awareness about the timing, severity, reversibility, and presentation of side effects, knowledge deficits that might affect their behavior with regard to recognizing and seeking care for potential immune-related adverse events,” explained the researchers.
Across the respondents, those with melanoma were more likely to know more about immunotherapy than those with lung cancer. Based on a knowledge score out of 100, patient with melanoma had a mean score of 74.7 compared with patients with lung cancer who had a mean score of 62.3.
Notably, a significant number of patients reported that they believed there was at least a 25% chance that immunotherapy would cure their cancer.
“Understanding of the goal of therapy is an important component of prognostic awareness. Patients with accurate understanding of the goal of their cancer treatment are more likely to receive care that is consistent with their preferences at the end of life,” wrote the researchers, who added, “The finding that most patients with melanoma (58%) perceived immunotherapy as curative likely reflects oncologists’ warranted optimism regarding the long-term durable responses that a significant minority of patients experience. Given the heterogeneity of possible treatment outcomes, however, future research should investigate how to best communicate uncertainty to patients.”
Approximately 1 in 3 patients when surveyed said that curing their cancer was the primary goal of their treatment, and 19% of patients with melanoma reported their oncologist telling them immunotherapy would cure their cancer.
Reference
Petrillo L, Zhou A, Sullivan R, et al. Knowledge about risks, benefits, and curative potential of immunotherapy among patients with advanced cancer. The Oncologist. Published online August 18, 2021. doi: 10.1002/onco.13945
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More